ELECTREON
10.11.2021 17:57:10 CET | Business Wire | Press release
ElectReon (TASE: ELWS.TA), the leading provider of in-road wireless electric vehicle (EV) charging technology for commercial, public service, and passenger vehicles, today announced that its wireless EV charging technology has been named as one of TIME's 100 Best Inventions of 2021 . The charging infrastructure, which can wirelessly charge EVs while in-motion and at-rest, was evaluated by TIME editors and correspondents around the world based on originality, creativity, effectiveness, ambition and impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006071/en/
ElectReon has been at the forefront of implementing their technology on public roads in multiple countries, providing accessible and flexible charging options that can be customized to meet the needs of unique EV fleet operators in a wide range of urban mobility, transit and logistics services.
“We honored by the recognition of ElectReon’s wireless charging solution by TIME as we work to spread awareness on the viability of this technology in maximizing fleet owner vehicle efficiencies, eliminating the cost of fuel, and reducing their full lifecycle carbon emissions,” said Oren Ezer, CEO of ElectReon. “As we rapidly scale our deployments around the world, we envision this technology to play a key role in accelerating the mass transition towards total electrification and we look forward to continuing to build the transportation infrastructure of tomorrow with the ongoing outstanding support from our industry and governmental partners we have experienced until now.”
“In addition to this great honor, it is clear that national governments are waking up to the significant value of in-road wireless charging and Electric Road Systems (ERS) and demonstrating their support,” said Ezer. National governments in European countries such as Sweden, Germany, Italy and France are announcing their plans to incorporate thousands of miles of ERS in their transportation strategies over the next decade to achieve net-zero carbon emissions. The French government, for example, just launched a call for automated road mobility, connected service infrastructures that enable low-carbon transport proposal projects, such as Electric Road demonstrators, among others. The Swedish Transport Authority just released a tender for 26 miles (42 km) of commercial ERS between the cities of Örebro and Hallsberg, as the country’s second phase of its ongoing national ERS deployment scaling, and several states in the US, including Michigan, are releasing a Request for Proposals (RFP) specifically for in-road dynamic wireless charging technology.
As one of the first and only companies able to demonstrate in-motion wireless charging on public roads, the company is currently working on various pre-commercial projects across the globe ranging from Germany , Italy , Sweden and Israel with plans of expansion into North America. Most recently, ElectReon announced the development of its wireless charging network to support 200 public buses in Tel Aviv in the company’s first fully commercial deal with one of Israel’s largest Public Transport Operators, Dan Bus Company. ElectReon also announced the recent addition of former President of Israel, Reuven “Ruvi” Rivlin , as the company’s president to facilitate relationships with world leaders to increase EV adoption, reduce fleet emissions, and accelerate ElectReon’s global impact.
To view the full TIME 2021 Best Inventions list visit: the TIME website .
About ElectReon
ElectReon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. ElectReon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006071/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
